evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

6 questions · 6 findings · 2 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 33.3%Low 4 · 66.7%Moderate 0 · 0%High 0 · 0%

Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Adverse events: malignancy · kidney transplant recipients

Calcineurin inhibitor (CNI) withdrawal + mammalian target of… showed no clear difference in adverse events: malignancy compared with standard dose CNI (low certainty).

1 finding from 1 review

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Adverse events: malignancy · kidney transplant recipients

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in adverse events: malignancy compared with standard dose CNI (low certainty).

1 finding from 1 review

Calcineurin inhibitors ± steroids vs placebo/no treatment/supportive treatment/steroids

Adverse events ‐ malignancy at 36 months · primary membranous nephropathy in adults with nephrotic syndrome

It is very uncertain whether calcineurin inhibitors ± steroids changes adverse events ‐ malignancy at 36 months compared with placebo/no treatment/supportive treatment/steroids (very low certainty).

1 finding from 1 review

Calcineurin inhibitors ± steroids vs alkylating agents ± steroids

Malignancy · primary membranous nephropathy in adults with nephrotic syndrome

It is very uncertain whether calcineurin inhibitors ± steroids changes adverse events ‐ malignancy (range 30 to 36 months compared with alkylating agents ± steroids (very low certainty).

1 finding from 1 review